ReviewOncotarget2015
Genetic/molecular alterations of meningiomas and the signaling pathways targeted.
Review in Oncotarget, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.
- EANO guideline on the diagnosis and management of meningiomas.Neuro-oncology · 2021Guideline
- Novel germline and somatic variants in familial and sporadic meningioma genes.NPJ genomic medicine · 2025Article
- Multiple meningiomas of different variants in a single patient: illustrative cases.Journal of neurosurgery. Case lessons · 2025Article
- Meningioma: Molecular Updates from the 2021 World Health Organization Classification of CNS Tumors and Imaging Correlates.AJNR. American journal of neuroradiology · 2025Review
- Article
- Malignant perineurioma derived from the retroperitoneum with an aggressive clinical course: a case report.Surgical case reports · 2024Article
- The Evolving Classification of Meningiomas: Integration of Molecular Discoveries to Inform Patient Care.Cancers · 2024Review
- Correlation of Molecular Status with Preoperative Olfactory Function in Olfactory Groove Meningioma.Cancers · 2024Article
- Radiotherapy intensification for atypical and malignant meningiomas: A systematic review.Neuro-oncology practice · 2024Review
- Noncoding RNA landscape and their emerging roles as biomarkers and therapeutic targets in meningioma.Molecular therapy. Oncology · 2024Review
- Drug target therapy and emerging clinical relevance of exosomes in meningeal tumors.Molecular and cellular biochemistry · 2024Review
- Brain Tumors: Development, Drug Resistance, and Sensitization - An Epigenetic Approach.Epigenetics · 2023Review
- Clinical, Histopathologic and Genetic Features of Rhabdoid Meningiomas.International journal of molecular sciences · 2023Article
- DNA methylation meningioma biomarkers: attributes and limitations.Frontiers in molecular neuroscience · 2023Review
- Identification of key genes of anti-programmed death ligand 1 for meningioma immunotherapy by bioinformatic analysis.Medical oncology (Northwood, London, England) · 2022Article
- Comprehensive overview of extracellular vesicle proteomics in meningioma: future strategy.Molecular biology reports · 2021Review
- Article
- Whole-Exome Sequencing Reveals Recurrent but Heterogeneous Mutational Profiles in Sporadic WHO Grade 1 Meningiomas.Frontiers in oncology · 2021Article
- A Practical Overview on the Molecular Biology of Meningioma.Current neurology and neuroscience reports · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meningiomas are usually considered to be benign central nervous system tumors; however, they show heterogenous clinical, histolopathological and cytogenetic features associated with a variable outcome. In recent years important advances have been achieved in the identification of the genetic/molecular alterations of meningiomas and the signaling pathways involved. Thus, monosomy 22, which is often associated with mutations of the NF2 gene, has emerged as the most frequent alteration of meningiomas; in addition, several other genes (e.g., AKT1, KLF4, TRAF7, SMO) and chromosomes have been found to be recurrently altered often in association with more complex karyotypes and involvement of multiple signaling pathways. Here we review the current knowledge about the most relevant genes involved and the signaling pathways targeted by such alterations. In addition, we summarize those proposals that have been made so far for classification and prognostic stratification of meningiomas based on their genetic/genomic features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.